Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
NCT04614558
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study wants to see if Isatuximab can help people with a kidney problem called MGRS. Isatuximab is only approved by the FDA to treat a type of cancer called multiple myeloma, so this study is testing to see if it could help with MGRS as well. This is a special type of testing called 'investigational'.
This study wants to see if Isatuximab can help people with a kidney problem called MGRS. Isatuximab is only approved by the FDA to treat a type of cancer called multiple myeloma, so this study is testing to see if it could help with MGRS as well. This is a special type of testing called 'investigational'.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
